Kura Oncology Long Term Debt 2012-2024 | KURA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Kura Oncology long term debt from 2012 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Kura Oncology long term debt from 2012 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$141B
Bristol Myers Squibb (BMY)	$113.2B
Gilead Sciences (GILD)	$112B
Vertex Pharmaceuticals (VRTX)	$105.5B
CSL (CSLLY)	$84.4B
Regeneron Pharmaceuticals (REGN)	$76.6B
GSK (GSK)	$68.6B
Argenex SE (ARGX)	$39.6B
Alnylam Pharmaceuticals (ALNY)	$30.7B
BioNTech SE (BNTX)	$29.5B
Biogen (BIIB)	$21.7B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$17.3B
Moderna (MRNA)	$16.3B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.7B
Incyte (INCY)	$13.6B
BioMarin Pharmaceutical (BMRN)	$12.8B
Sarepta Therapeutics (SRPT)	$11.9B
Insmed (INSM)	$11.7B
Bio-Techne Corp (TECH)	$11.6B
Exact Sciences (EXAS)	$10.5B
Exelixis (EXEL)	$10.3B
QIAGEN (QGEN)	$10.2B
Vaxcyte (PCVX)	$10.1B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Intra-Cellular Therapies (ITCI)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.5B
Repligen (RGEN)	$8.7B
Ascendis Pharma (ASND)	$7.8B